Droniva 150 mg (Tablet)
1 tablet kit: ৳ 700.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Ibandronic acid |
| Company | Navana pharmaceuticals ltd |
Indications
- Treatment of osteoporosis in women (specially postmenopausal)
- Prevention of osteoporosis in women (specially postmenopausal)
- Prevention and treatment of osteoporosis in men
Pharmacology
- Inhibition of bone resorption
- Prevents experimentally induced bone destruction
- Highly potent inhibitor of osteoclastic activity
Dosage & Administration
- Recommended dose of one 150 mg film-coated tablet once a month
- Tablet should be taken 60 minutes before the first food or drink of the day
- Swallow tablet with a full glass of plain water
- Patients should not lie down for 60 minutes after taking the tablet
Interaction
- Potential interference with the absorption of Droniva by calcium supplements and some oral medications
- Absence of interaction potential with tamoxifen or hormone replacement therapy
- Increased bioavailability with co-administration of i.v. ranitidine
Contraindications
- Known hypersensitivity to ibandronic acid or to any of the excipients
- Uncorrected hypocalcemia
- Abnormalities which delay esophageal emptying
- Inability to stand or sit upright for at least 60 minutes
Side Effects
- Dyspepsia
- Nausea
- Diarrhea
- Abdominal pain
- Muscle aches
- Headaches
- Dizziness
Pregnancy & Lactation
- Not recommended during pregnancy
- Not recommended during lactation
- No clinical experience in pregnant women
- Low concentration in breast milk
Precautions & Warnings
- Treatment of hypocalcemia and other disturbances of bone and mineral metabolism before starting Droniva therapy
- Caution in patients with active upper gastrointestinal problems
- Risk of severe esophageal adverse experiences
- Potential risk of osteonecrosis of the jaw
Use in Special Populations
- No dosage adjustment for patients with mild or moderate renal impairment
- No dosage adjustment for patients with hepatic impairment
- No dosage adjustment for elderly
- Safety and efficacy not established in patients less than 18 years old
Overdose Effects
- No specific information available on treatment
- Potential upper gastrointestinal adverse events
- Milk or antacids should be given to bind Droniva
Therapeutic Class
- Bisphosphonate preparations
Storage Conditions
- Keep below 30°C temperature
- Away from light & moisture
- Keep out of the reach of children